| 000 | 01897 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515204635.0 | ||
| 264 | 0 | _c20100422 | |
| 008 | 201004s 0 0 eng d | ||
| 022 | _a1555-2101 | ||
| 024 | 7 |
_a10.4088/JCP.08m04942gre _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMcElroy, Susan L | |
| 245 | 0 | 0 |
_aA double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). _h[electronic resource] |
| 260 |
_bThe Journal of clinical psychiatry _cFeb 2010 |
||
| 300 |
_a163-74 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntidepressive Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntidepressive Agents, Second-Generation _xadverse effects |
| 650 | 0 | 4 |
_aAntimanic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBipolar Disorder _xdrug therapy |
| 650 | 0 | 4 |
_aDibenzothiazepines _xadverse effects |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aParoxetine _xadverse effects |
| 650 | 0 | 4 | _aPlacebos |
| 650 | 0 | 4 | _aPsychiatric Status Rating Scales |
| 650 | 0 | 4 | _aQuetiapine Fumarate |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aWeisler, Richard H | |
| 700 | 1 | _aChang, William | |
| 700 | 1 | _aOlausson, Bengt | |
| 700 | 1 | _aPaulsson, Björn | |
| 700 | 1 | _aBrecher, Martin | |
| 700 | 1 | _aAgambaram, Vasavan | |
| 700 | 1 | _aMerideth, Charles | |
| 700 | 1 | _aNordenhem, Arvid | |
| 700 | 1 | _aYoung, Allan H | |
| 773 | 0 |
_tThe Journal of clinical psychiatry _gvol. 71 _gno. 2 _gp. 163-74 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4088/JCP.08m04942gre _zAvailable from publisher's website |
| 999 |
_c19494633 _d19494633 |
||